Abstract
INTRODUCTION
Liver fibrosis is a common pathological condition resul ting from chronic liver injury stemming from a variety of etiological factors. Hepatic stellate cells (HSCs) play a key role in the progression of liver fibrosis, and are thought to be its primary effector cells [1] . In chronic liver diseases (CLDs), quiescent HSCs are activated and change to myofibroblastlike cells, which are proliferative, contractile, and secrete increased levels of more extracellular matrix (ECM) [2] . Angiogenesis is widely noted in CLDs, and influences liver fibrosis and portal hypertension (PHT) [3] . HSCs are liver specific pericytes that participate in angiogenesis and sinusoidal remodeling. The primary pathological feature of sinusoidal remodeling is sinusoidal capillarization and coverage of the vessels with contractile HSCs [4] . HSCs reduce the diameter of sinusoids after contraction, causing a functional change in modulating the hepatic tone and increasing intrahepatic vascular resistance (IHVR), ultimately contributing to PHT [5] . HSCs occupy a crossroad at the intersection between inflammation, angiogenesis, and fibrosis [6] , and activation of HSCs is a key event mediating increased IHVR [7] . Thus, activated HSCs are a potent therapeutic target for the treatment of CLDs.
Metformin is the firstline drug recommended for the treatment of diabetes. Previous studies have demonstrated that metformin has a wide range of pharmacological activities beyond its antidiabetic effects. The beneficial effects of metformin in hepatic disorders have been previously confirmed for reducing fibrosis [8, 9] , IHVR, and therefore PHT in cirrhosis [10] , and decreasing hepatocellular carcinoma risk [11] . Metformin is a potent therapeutic approach for CLDs, but the mechanisms underlying its effects are still unclear, especially in the treatment of PHT. Further studies are needed to investigate the effect of metformin in CLDs.
Plateletderived growth factor (PDGF) signaling is among the most well characterized pathways of HSC activation. It induces activation of the extracellular signalregulated kinase (ERK) and the Akt/mammalian target of rapamycin (mTOR) pathways, which are associated with cellular proliferation and migration [12] . Studies have also linked ERK and mTOR signaling to vascular endothelial gowth factor (VEGF) expression during angiogenesis [13, 14] . Activation of adenosine monophosphateactivated protein kinase (AMPK) inhibits the proliferation and migration of HSCs induced by PDGF, and this effect is related to the inhibition of the Akt and ERK pathways [15] . Metformin is known to activate AMPK, therefore, we speculated that met formin may regulate the fibrogenic response of HSCs and have an antiangiogenic effect.
In the present study, we investigated the effect of metformin on activated HSCs. The inhibitory effects of metformin on the activation, proliferation, motility, contraction, and ECM secretion of HSCs and HSCbased angiogenesis were evaluated. We also investigated the underlying mechanisms, with a focus on AMPK and the downstream AKT/mTOR and ERK signaling pathways.
MATERIALS AND METHODS

Animals
Thirty male C57BL/6 mice weighing 2022 g were purchased from the Central Animal Care Facility of Shandong University and randomly divided into three groups (a control group, a CCl4 group, and a metformin group, n = 10 in each group). The animals were housed in an airconditioned room at 2325 ℃ with a light/dark (12 h:12 h) cycle for one week prior to the initiation of the experiment. All animals received appropriate care during the study, with free access to chow and water. The liver fibrosis model was induced by intraperitoneal injection of carbon tetrachloride (CCl4, 1 µl/g, Sinopharm, Beijing, China) dissolved 1:1 (v/v) in olive oil twice per week, while the control mice were injected with olive oil alone. Mice in the metformin group were treated with metformin (SigmaAldrich, Saint Louis, MO, United States) in drinking water (1 g/L) at the same time. All mice were sacrificed at the end of 6 wk. A portion of liver tissue was fixed in 4% paraformaldehyde and then embedded in paraffin. The other liver tissues were stored at 80 ℃.
Cell culture
The HSC cell line LX2 (a kind gift from Professor Weifen Xie, Changzheng Hospital, the Second Military Medical University) and human umbilical vascular endothelial cells (HUVECs, ATCC, Manassas, VA, United States) were cultured in Dulbecco's modified Eagle's medium (DMEM; Gibco, Grand Island, NY, United States) supple mented with 10% fetal bovine serum (FBS; Gibco) in an incubator at 37 ℃ with 5% CO2 and 90% humidity.
CCK-8 assay
First, 5 × 10 3 LX2 cells were seeded in 96well plates and incubated overnight, and then the medium was changed to fresh medium containing different concen trations of metformin. After incubation for 24 h, 10 µl of CCK8 (Dojindo, Japan) was added to each well. The optical density (OD) values were measured every 30 min with a spectrophotometer (Thermo Fisher, Finland) at 450 nm. The OD values at 2 h were chosen for analysis.
Migration and invasion assay
A scratch test was used for HSC migration assay. Cells (5 × 10
5
) were seeded in 6well plates, incubated overnight to cover the full plate, and then serum starved for 8 h. After making scratch wounds, plates were washed three times with PBS. Cells were treated with or without 10 ng/ml PDGFBB (PeproTech, Rocky Hill, NJ, United States) for 24 h. Different concentrations of metformin were added to the medium 2 h before the PDGFBB addition. Images were acquired at 0 and 24 h. The Transwell (8 µm pore size, Costar) assay was used to test the invasive ability of HSCs. HSCs were serumfree for 6 h and then harvested. Cells (1 × 10 5 ) in 100 µl serumfree medium were seeded in the upper chambers with the Matrigel (BD Bioscience, Bedford, MA, United States) membrane and different concentrations of metformin, and the lower chambers were loaded with DMEM with or without 10% FBS. After incubation for 24 h, cells that migrated through the membrane were fixed and stained with hematoxylin. Cell numbers were counted under a microscope (Olympus, Japan).
Collagen gel contraction assay
Rat tail tendon collagen type Ⅰ was obtained from Sybio (Hangzhou, China). The collagen gel was prepared in 24well plates. We used 0.1 mol/L NaOH to adjust the pH and 10 × PBS to adjust the solution to physiological strength. The mixed solution (500 µL) was added to each plate and incubated at 37 ℃ for 1 h to allow gelatinization. LX2 cells (1 × 10 5 ) in 1000 µL of medium were seeded on the gel and incubated overnight. Cells were starved for 8 h in DMEM, and then the DMEM was replaced with fresh medium with 1% FBS and different concentrations of metformin. PDGF BB (10 ng/mL) was added to the medium, except in the control group, 2 h after metformin addition. The tip of a 200 µl pipette was used to gently detach the gel from the plates. After incubation for 24 h, the areas of the gels were measured. 
Enzyme-linked immunosorbent assay
Tube formation assay
A 96well plate was coated with 50 µl of Matrigel, and then placed in an incubator at 37 ℃ for 1 h. Cells were treated in the same way as in the ELISA assay, and the supernatant was collected. Conditioned medium was generated from supernatant diluted 4:1 (v/v) in DMEM with 10% FBS. HUVECs were harvested and suspended in the conditioned medium. HUVECs (2 × 10 4 ) in 100 µl of conditioned medium were seeded in 96well plates and incubated at 37 ℃. The cells were States). The primers used in this study are presented in Table 1 . Expression of target genes was normalized to expression of GAPDH by the 2 ΔCT method.
Histopathological and immunohistochemical analyses
Liver specimens embedded in paraffin were cut into 4 µmthick sections. The specimens were stained with hematoxylin and eosin and Sirius Red. Immunohi stochemistry (IHC) was performed using a 2step plus PolyHRP AntiMouse/Rabbit IgG Detection system (Zhongshan Golden Bridge, Beijing, China), according to the manufacturer's instructions. Sections were incubated with antibodies against αSMA, fibronectin, and VEGF, and the blots were developed with a DAB kit (Zhongshan Golden Bridge, Beijing, China).
Statistical analysis
All data are presented as the mean ± SEM from at least three independent experiments. Statistics were analyzed using GraphPad Prism 5.0 and SPSS19.0 software. Statistical significance was determined by oneway analysis of variance (ANOVA) followed by Dunnett's test. A pvalue < 0.05 was considered statistically significant.
RESULTS
Metformin decreases the activation of HSCs, reduces the deposition of ECM, and inhibits angiogenesis in CCl4-treated mice
Liver specimens from mice exposed to CCl4 showed hepatocellular degeneration with excessive accumulation of connective tissue, the formation of fibrotic septa, and infiltration of inflammatory cells. Metformin treat ment attenuated the fibrotic level of the fibrotic tissue, the appearance of degenerated hepatocytes, and inflammatory cell infiltration ( Figure 1A ). Increased collagen deposition was observed in CCl4induced fibrotic mice, which could be suppressed by metformin ( Figure 1B) . A similar effect of metformin on fibronectin was seen in IHC ( Figure 1D ). As shown in Figure 1E , fibrotic mice expressed more VEGF, indicating more intrahepatic angiogenesis than the control group. Treatment with metformin significantly suppressed expression of VEGF. Mice exposed to CCl4 increased αSMA at both the protein and mRNA levels, while cotreatment with metformin reduced this effect ( Figure 2A and B), which was also confirmed by IHC ( Figure 1C ). The CCl4induced increase in collagen I mRNA expression was reduced by cotreatment with metformin. Taken together, metformin decreased the activation of HSCs, reduced the deposition of ECM, and inhibited angiogenesis in CCl4treated mice. Therefore, metformin attenuated CCl4induced liver fibrosis in mice.
Metformin inhibits the proliferation of activated HSCs
HSCs were treated with different concentrations monitored every 2 h for 12 h under a microscope. Images of the tube formation were acquired at 8 h.
Western blot analysis
Total protein was extracted with RIPA buffer, and the protein concentration was measured by the bicinchoninic acid method. Equal amounts of proteins were loaded and separated by SDSPAGE, and then transferred onto a PVDF membrane. The membrane was blocked in TBST buffer with 5% nonfat milk for 1 h and incubated with different antibodies overnight at 4 ℃. Primary antibodies against αSMA (143951AP), fibronectin (660421IG), and collagen type Ⅰ (14695 1AP) were obtained from Proteintech (Wuhan, China). Primary antibodies against pERK1/2 (#4376), pAkt (#4060), pAMPK (#2535), pmTOR (#5536), ERK1/2 (#4695), Akt (#4691), AMPK (#5832), and mTOR (#2983) were obtained from CST (Boston, MA, United States). Primary antibody against VEGF (ab46154) was obtained from Abcam (Cambridge, CA, United States). Primary antibody against HIF1α (NB100105) was obtained from Novus (Littleton, CO, United States). Primary antibody against glyceraldehyde 3phosphate dehydrogenase (GAPDH) and horseradish peroxidase (HRP)conjugated secondary antibody were obtained from Zhongshan Golden Bridge (Beijing, China). The HRPconjugated secondary antibodies were goat antirabbit or antimouse antibody depending on the primary antibodies. AICAR (an AMPK activator) and rapamycin (an mTOR inhibitor) were obtained from Selleck (Houston, TX, United States). PD98059 (an ERK inhibitor) and LY294002 (an AKT inhibitor) were obtained from MCE (Monmouth Junction, NJ, United States). Antibody bands were detected by enhanced chemiluminescence with Amersham Imager 600 (GE Healthcare, United States). GAPDH in the same membrane was used as an internal control, and all bands were normalized to its expression.
Reverse transcription-polymerase chain reaction
Total RNA was extracted with TRIzol reagent (Takara, Japan) from frozen liver tissues and was reverse transcribed to cDNA using an RT reagent kit (Takara, Japan). Amplifications were detected using a the SYBR Premix Ex Taq kit (Takara, Japan) on a LightCycler 480 RealTime PCR system (Roche Diagnostics, United
α-SMA: Alpha-smooth muscle actin; COL1A1: Collagen type 1 alpha 1.
Table 1 The primers used for RT-PCR analysis
S-R staining (fold) HSCs were treated with or without 10 ng/ml PDGF-BB for 24 h, and the effect of metformin (1, 2, 5, and 10 mmol/L) on the expression levels of α-SMA, collagen type Ⅰ, and fibronectin (FN) were measured by Western blot ( a P < 0.05 vs the control group, c P < 0.05 and d P < 0.01 vs the PDGF-BB only group); E: HSCs were treated with a series of concentrations ranging from 1 mmol/L to 100 mmol/L of metformin for 24 h, and the proliferation was measured by CCK-8 assays. HSCs: Hepatic stellate cells.
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(1 mmol/L to 100 mmol/L) of metformin for 24 h ( Figure 2E ). The proliferation of HSCs was inhibited by metformin in a dosedependent manner, and the IC50 was 50.01 mmol/L.
Metformin suppresses the activation of HSCs and decreases the expression of ECM in vitro
The protein levels of αSMA, collagen type Ⅰ, and fibronectin were measured by Western blot ( Figure  2C and D) . PDGFBB upregulated the expression of αSMA, while treatment with metformin at 5 mmol/L and 10 mmol/L suppressed this increase, from 113.5% ± 4.66% to 84.87% ± 6.63% and 58.79% ± 12.64%, respectively (p < 0.05). Collagen type I and fibronectin are the major components of the ECM, and HSCs expressed increased levels of these protein after co incubation with PDGFBB. Metformin decreased the protein levels at doses of 2, 5, and 10 mmol/L. These results indicated that metformin suppressed the activation of HSCs and the secretion of ECM in vitro.
Metformin decreases the migration and invasion of HSCs
The migration rate of HSCs was significantly increased by PDGFBB treatment compared with that of the control group (26.38% ± 2.98% to 48.05% ± 3.67%, p < 0.01). Treatment with metformin at 5 mmol/L and 10 mmol/L reduced PDGFBBinduced migration, from 48.05% ± 3.67% to 21.67% ± 2.73% and 14.99% ± 0.25% (p < 0.01), respectively ( Figure 3A and C) . As shown in Figure 3B , cells that migrated through the matrigel membrane decreased from 1352% ± 62.87% to 748.0% ± 76.18%, 453.0% ± 4.58%, and 190.0% ± 14.73% (p < 0.01) compared with the control group when treated with metformin at 1, 5, and 10 mmol/L, respectively ( Figure 3D ). These findings indicated that metformin decreased the motility of HSCs.
Metformin inhibits the contraction of HSCs
We assessed the inhibitory effect of metformin on the contractility of HSCs by collagen gel contraction assay. PDGFBB caused a significant increase in cell contractility, while coculture with metformin neut ralized these effects ( Figure 4A and C) . PDGFBB treatment enhanced the contraction rate of HSCs from 47.43% ± 2.13% to 70.25% ± 1.35% (p < 0.01), while treatment with metformin at 1, 5, and 10 mmol/L attenuated the contraction rate to 49.70% ± 6.59% (p < 0.05), 44.73% ± 4.65%, and 42.26% ± 3.28% (p < 0.01), respectively.
Metformin decreases the expression of VEGF in HSCs through inhibition of HIF-1α in both PDGF-BB and hypoxic conditions
CoCl2· 6H2O (150 µmol/L) was added to the medium to mimic hypoxic conditions [16, 17] . HSCs expressed more VEGF when incubated with PDGFBB or CoCl2 compared with the control group, and this effect was associated with an increased level of HIF1α ( Figure  5A and B). Metformin decreased the level of HIF1α and further reduced the expression of VEGF in HSCs. Treatment with metformin at 5 and 10 mmol/L had an inhibitory effect on VEGF expression in both PDGFBB and hypoxic conditions.
Metformin down-regulates VEGF secretion by HSCs and inhibits angiogenesis in hypoxic conditions in vitro
The VEGF protein level in the supernatant was increased from 148.96 ± 50.62 pg/ml to 343.52 ± 25.91 pg/ml (p < 0.01) when CoCl2 (150 µmol/L) was added to the medium, but coculture with metformin at 5 mmol/L and 10 mmol/L decreased VEGF levels to 254.40 ± 16.91 pg/mL and 229.04 ± 1.62 pg/mL, respectively (p < 0.01) ( Figure 5C ). Figure 5D and E).
Metformin inhibits the fibrogenic response of HSCs through inhibition of the Akt/mTOR and ERK pathways via the activation of AMPK
Metformin increased the phosphorylation of AMPK in a dosedependent manner ( Figure 6C ). After stimulation with PDGFBB, the levels of pAkt, pmTOR, and pERK were significantly increased compared with those of the control group, while cotreatment with metformin decreased these effects ( Figure 6A and E). The Akt/mTOR and ERK pathways are associated with cell proliferation, migration, and phenotypic change in HSCs. To further confirm these effects, we used various indicated inhibitors to treat HSCs ( Figure 7A and C). LY294002 (an Akt inhibitor, 20 µmol/L) and rapamycin (an mTOR inhibitor, 100 nmol/L) inhibited the activation of HSCs, decreased ECM secretion, and reduced the expression of HIF1α and VEGF. Moreover, LY294002 inhibited the contraction of HSCs ( Figure 4B and D). PD98059 (an ERK inhibitor, 10 µmol/L) had a similar effect as LY294002, except that it could not decrease the secretion of collagen type I. Additionally, AICAR (500 µmol/L), another AMPK activator, mimicked the effect of metformin. In conclusion, PDGFBB increased the fibrogenic response of HSCs through activating the downstream Akt/mTOR and ERK pathways, while metformin inhibited these effects via activation of AMPK.
Metformin decreases VEGF expression by activated HSCs by down-regulating the mTOR/HIF-1α and ERK/ HIF-1α pathways under hypoxic conditions
The levels of pmTOR and pERK were significantly increased when compared with the control group under hypoxic conditions, while no change was found in the phosphorylation of Akt ( Figure 6B and D) . Metformin increased the phosphorylation of AMPK and inhibited the activation of pmTOR and pERK. PD98059 and rapamycin decreased the expression of HIF1α and VEGF. LY294002 inhibited the activation of pAkt and the downstream pmTOR, which therefore decreased the expression of HIF1α and VEGF. AICAR had a similar effect as metformin under these conditions ( Figure 7D and F). These results indicated that metformin decreased VEGF expression by activated HSCs by downregulating the mTOR/HIF1α and ERK/ HIF1α signaling pathways under hypoxic conditions.
DISCUSSION
The prime determinant of PHT is increased IHVR, which is thought to be generated by the following two factors: structural (distortion of the liver vascular architecture caused by fibrosis, scarring, and nodule formation) and functional (hepatic sinusoidal cellular alterations that promote constriction of the hepatic sinusoids) components [18] . Research has shown that activation of HSCs is a key event mediating augmented IHVR [7] . We designed this study to investigate the role of metformin in activated HSCs. We found that metformin could attenuate the fibrogenic response of HSCs and decrease IHVR. Our research indicated that metformin treatment may be a potent therapeutic approach to treating liver fibrosis and PHT.
First, we used a fibrotic mouse model to determine whether metformin had effects on liver fibrosis. Mice injected with CCl4 for 6 wk developed marked fibrosis compared with the control group, while cotreatment with metformin attenuated histopathologic features of fibrosis. αSMA, a marker of HSC activation, was inhibited by metformin at both the protein and mRNA levels. Sirius Red staining showed that collagen deposition was also decreased, as well as the mRNA level of collagen type Ⅰ. Moreover, VEGF expression was upregulated in fibrotic mice, which was decreased by metformin treatment. Therefore, metformin could alleviate the progression of liver fibrosis in fibrotic mice. A recent study also showed that metformin mitigated CCl4induced liver fibrosis in mice. The antifibrogenic response was reported to primarily involve suppression of ECM deposition, and this effect might have resulted from suppressed TGFb1/Smad3 signaling [8] ; this was supported by a previous in vitro study [9] . In our study, we found that metformin could also inhibit the angiogenesis in liver fibrosis, indicating that metformin may attenuate liver fibrosis in other ways. The PDGF signaling pathway is among the most well character ized pathways involved in HSC activation; PDGF BB is the most potent stimulator of HSC growth and intracellular signaling [1] , and blocking of PDGF signaling ameliorates experimental liver fibrogenesis [19] . As described above, we speculated that metformin could regulate the fibrogenic response of HSCs and have an antiangiogenic effect via PDGF and its downstream pathways. Therefore, we performed an in vitro study to further explain the effect of metformin on activated HSCs and investigate the possible signaling pathways involved. We used PDGFBB to stimulate HSCs in vitro. PDGFBB upregulated the expression of αSMA, as well as type Ⅰ collagen and fibronectin, in HSCs, while these protein levels were decreased when treated with metformin. These results are in agreement with our animal experiments. Caligiuri showed that activation of AMPK modulated the activated phenotype change of HSCs caused by PDGFBB [15] . In this study, PDGF induced activation of the downstream molecules ERK and Akt/mTOR in activated HSCs, which are associated with cellular proliferation, migration, and phenotype changes. Metformin inhibited the activation of ERK and Akt/mTOR by activating AMPK. To further analyze the role of the signaling pathways, we used various indicated inhibitors to determine whether the signaling pathways could affect activated HSCs. LY294002 and rapamycin inhibited the expression of αSMA, Li Z et al . Effect of metformin on activated HSCs
collagen Ⅰ, and fibronectin. PD98059 had a similar effect, except for the expression of collagen type Ⅰ.
Furthermore, AICAR, another AMPK activator, could imitate the effect of metformin on activated HSCs. Metformin inhibited activation and ECM secretion of HSCs. This effect was mediated by the activation of AMPK, thereby inhibiting the activation of ERK and Akt/mTOR by PDGFBB. In liver cirrhosis, an imbalance between vasocon strictors and vasodilators makes HSCs more contractile, which increases IHVR and aggravates PHT. Metformin has been reported to attenuate contractile responses in rat aortas [20] , and to reduce pulmonary artery contraction in pulmonary arterial hypertension [21] . Therefore, we used a collagen gel contraction assay to evaluate the effect of metformin on the contraction of HSCs. Our results showed that metformin inhibited the contraction of HSCs caused by PDGFBB. The RhoA/Rock pathway is the contractile pathway in vascular smooth muscle that is also expressed in HSCs [22] . Sorafenib can down regulate Rho kinase by inhibiting the ERK pathway in secondary biliary cirrhotic rats and further reduce portal 
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pressure [23] . Metformin can decrease the activation of ERK caused by PDGFBB; therefore, we speculated that the inhibitory effect of metformin on the contraction of HSCs were due in part to the inhibition of the ERK pathway. To confirm this effect, we used PD98059 to treat HSCs stimulated with PDGFBB. PD98059 inhibited the contraction of HSCs, as expected. There have also been studies that linked the inhibition of the Akt pathway to attenuation of contraction [24, 25] , and this effect may be associated with the Akt/Ltype calcium channel and the Akt/RhoA/Rho kinase pathways [26, 27] . In our research, LY294002 could also inhibit the contraction of HSCs, indicating that the Akt pathway was also involved in modulating the contraction of HSCs.
In addition, AICAR had a similar effect to metformin on the contraction of HSCs. Thus, metformin inhibits the contraction of activated HSCs, which can decrease IHVR and lower portal pressure.
PDGF can promote HSCs to develop an angiogenic phenotype via modulating HSCbased vascular tube formation and increasing coverage of sinusoids, with resulting effects on vascular permeability, vessel mutation, and portal pressure regulation [6, 28] . Activated HSC recruitment to liver sinusoidal epithelial cells is an important step in sinusoidal remodeling, and PDGF may be the most important growth factor in this process [29] . In our study, metformin decreased the motility of HSCs. Moreover, metformin decreased the level of VEGF secreted by HSCs, and inhibited angiogenesis in vitro. Taken together, we showed that metformin could inhibit the angiogenic properties of HSCs.
VEGF plays a predominant role in the initial stages of angiogenesis [3] . Reports have shown that PDGF can increase the HIF1α and VEGF protein levels in activated HSCs [30] . PDGF can also stimulate VEGF expression and HSCdriven vascularization through signals mediated by ERK and mTOR [31] . In our study, the AKT/mTOR and ERK pathways were upregulated by PDGF and caused increased levels of HIF1α and VEGF in HSCs. The activation of AMPK by metformin decreased the upregulation of VEGF by PDGF. This result was partly in agreement with the research by Zhang et al [32] , who found that curcumin interrupted the PDGFbR/ERK and mTOR pathways, leading to reductions in VEGF expression in HSCs. As hypoxia is the most potent stimulus for VEGF expression, we further used CoCl2 to mimic a hypoxic environment. Hypoxia stabilized HIF 1α and upregulated the expression of VEGF in our study. The protein level of VEGF in the HSCs and the medium was significantly higher than that in the control group, and the phosphorylation of ERK and mTOR was also increased. Cotreatment with the AMPK activator metformin inhibited the increase of HIF1α, VEGF, and the activation of ERK and mTOR. In addition, AICAR, LY294002, PD98059, and rapamycin could also inhibit the expression of HIF1α and VEGF. These results indicated that metformin could decrease the VEGF levels secreted by HSCs, and this effect was partly mediated by the ERK/HIF1α and mTOR/HIF1α pathways. Finally, we used tube formation assays to analyze angiogenesis in vitro. When HUVECs were cultured with conditioned medium from HSCs treated with metformin under hypoxic conditions, tube formation was less than that in medium without metformin. AICAR had a similar effect to metformin. Therefore, metformin could inhibit PDGF and hypoxiainduced VEGF expression in HSCs, thus decreasing HSCbased angiogenesis. These effects were mediated through the inhibition of the ERK/HIF1α and mTOR/HIF1α pathways by activation of AMPK.
In conclusion, metformin can inhibit the activation, proliferation, motility, and contraction of HSCs, redu ce the secretion of ECM, attenuate HSC angiogenic properties, and decrease HSCbased angiogenesis. Metformin has effects on both structural and functional components of IHVR, suggesting a novel therapeutic approach for the treatment of liver fibrosis and PHT.
ARTICLE HIGHLIGHTS
Research background
Activation of hepatic stellate cells (HSCs) contributes to liver fibrosis and portal hypertension, and it is a therapeutic target for the treatment of chronic liver diseases (CLDs). Previous studies have demonstrated that metformin has a wide range of pharmacological activities beyond its antidiabetic effects. It may therefore represent a potent therapeutic approach to CLDs, but the mechanisms underlying its effects are still unclear.
Research motivation
This study was performed to investigate the effect of metformin on activated HSCs and clarify its molecular mechanisms.
Research objectives
The inhibitory effects of metformin on the activation, proliferation, motility, contraction, extracellular matrix (ECM) secretion of HSCs and HSCbased angiogenesis were evaluated. We also characterized its underlying mechanisms with a focus on AMPK and downstream AKT/mTOR and ERK signaling pathways.
Research methods
The effect of metformin on activated HSCs were investigated in vivo and in vitro. A fibrotic mouse model was treated with or without metformin, and the effect of metformin on liver fibrosis was evaluated. The HSC cell line LX-2 was used for in vitro studies. The effect of metformin on cell proliferation was detected by CCK8 assay. Cell motility was measured by scratch tests and Transwell assays. Collagen gel contraction assays were performed to assess the effect of metformin on cell contraction. Expression of α-SMA, collagen type Ⅰ, and fibronectin was determined by Western blot analysis. We also analyzed the effect of metformin on HSC-based angiogenesis in both PDGF and hypoxic conditions. The phosphorylation levels of AMPK, AKT, mTOR, and ERK were measured by Western blot analysis. We also used the indicated pharmacologic inhibitors and agonists to confirm our findings.
Research results
Metformin decreased the activation of HSCs, reduced the deposition of ECM, and inhibited angiogenesis in fibrotic mice. PDGF-BB promoted the fibrogenic response of HSCs, while metformin inhibited the activation, proliferation, migration, and contraction of HSCs, reduced their secretion of ECM, and decreased HSC-based angiogenesis. These inhibitory effects were mediated by inhibition of the Akt/mTOR and ERK pathways via the activation of AMPK.
Research conclusions
Metformin attenuates the fibrogenic response of HSCs in vivo and in vitro, and may therefore be useful for the treatment of chronic liver diseases.
Research perspective
This study investigated the inhibitory effect of metformin on activated HSCs and the possible signaling pathways involved. The results strongly confirmed the potential use of metformin for the treatment of CLDs. In future studies, we will provide more evidence for the use of metformin, especially in the treatment of portal hypertension. The effect of metformin on liver sinusoidal endothelial cells will also be analyzed.
